These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

645 related items for PubMed ID: 28662986

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cessation of extracorporeal photopheresis in chronic lung allograft dysfunction: effects on clinical outcome in adults.
    Robinson CA, Huber L, Murer C, Schuurmans M, Kohler M, Hofbauer G, Benden C.
    Swiss Med Wkly; 2017; 147():w14429. PubMed ID: 28488260
    [Abstract] [Full Text] [Related]

  • 4. Early extracorporeal photopheresis treatment is associated with better survival in patients with chronic or recurrent acute lung allograft dysfunction.
    Gautschi F, Vogelmann T, Ortmanns G, Knörr F, Steinack C, Hage R, Nägeli M, Schuurmans MM.
    J Clin Apher; 2024 Jun; 39(3):e22128. PubMed ID: 38829041
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The efficacy of photopheresis for bronchiolitis obliterans syndrome after lung transplantation.
    Morrell MR, Despotis GJ, Lublin DM, Patterson GA, Trulock EP, Hachem RR.
    J Heart Lung Transplant; 2010 Apr; 29(4):424-31. PubMed ID: 19853479
    [Abstract] [Full Text] [Related]

  • 7. Extracorporeal photopheresis (ECP) in the treatment of chronic lung allograft dysfunction (CLAD): a prospective, multicentre, open-label, randomised controlled trial studying the addition of ECP to standard care in the treatment of bilateral lung transplant patients with CLAD (E-CLAD UK).
    Fisher AJ, White M, Goudie N, Kershaw A, Phillipson J, Bardgett M, Lally J, Bevin-Nicholls A, Chadwick T, Bryant A, Russell S, Smith H, Frisby L, Errington R, Carby M, Thompson R, Santhanakrishnan K, Parmar J, Lordan JL, Vale L, Hancock H, Exley C, Gennery AR, Wason JM.
    BMJ Open Respir Res; 2024 May 09; 11(1):. PubMed ID: 38724453
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-Term Off-Line Extracorporeal Photochemotherapy in Patients with Chronic Lung Allograft Rejection Not Responsive to Conventional Treatment: A 10-Year Single-Centre Analysis.
    Del Fante C, Scudeller L, Oggionni T, Viarengo G, Cemmi F, Morosini M, Cascina A, Meloni F, Perotti C.
    Respiration; 2015 May 09; 90(2):118-28. PubMed ID: 26112178
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of Extracorporeal Photopheresis in Patients With Bronchiolitis Obliterans Syndrome After Lung Transplantation.
    Pecoraro Y, Carillo C, Diso D, Mantovani S, Cimino G, De Giacomo T, Troiani P, Shafii M, Gherzi L, Amore D, Rendina EA, Venuta F, Anile M.
    Transplant Proc; 2017 May 09; 49(4):695-698. PubMed ID: 28457374
    [Abstract] [Full Text] [Related]

  • 11. Phenotyping established chronic lung allograft dysfunction predicts extracorporeal photopheresis response in lung transplant patients.
    Greer M, Dierich M, De Wall C, Suhling H, Rademacher J, Welte T, Haverich A, Warnecke G, Ivanyi P, Buchholz S, Gottlieb J, Fuehner T.
    Am J Transplant; 2013 Apr 09; 13(4):911-918. PubMed ID: 23406373
    [Abstract] [Full Text] [Related]

  • 12. Are we near to an effective drug treatment for bronchiolitis obliterans?
    Verleden GM, Vos R, Dupont L, Van Raemdonck DE, Vanaudenaerde BM, Verleden SE.
    Expert Opin Pharmacother; 2014 Oct 09; 15(15):2117-20. PubMed ID: 25154562
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Management of chronic rejection after lung transplantation.
    Bedair B, Hachem RR.
    J Thorac Dis; 2021 Nov 09; 13(11):6645-6653. PubMed ID: 34992842
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of extracorporeal photopheresis and alemtuzumab for the treatment of chronic lung allograft dysfunction.
    Moniodis A, Townsend K, Rabin A, Aloum O, Stempel J, Burkett P, Camp P, Divo M, El-Chemaly S, Mallidi H, Rosas I, Fuhlbrigge A, Koo S, Goldberg HJ.
    J Heart Lung Transplant; 2018 Mar 09; 37(3):340-348. PubMed ID: 28431983
    [Abstract] [Full Text] [Related]

  • 18. Extracorporeal photopheresis after lung transplantation: a 10-year single-center experience.
    Benden C, Speich R, Hofbauer GF, Irani S, Eich-Wanger C, Russi EW, Weder W, Boehler A.
    Transplantation; 2008 Dec 15; 86(11):1625-7. PubMed ID: 19077900
    [Abstract] [Full Text] [Related]

  • 19. Extracorporeal photopheresis as second-line treatment therapy in life-threatening primary graft dysfunction following lung transplantation.
    Robinson CA, Inci I, Naegeli M, Murer C, Schuurmans MM, Urosevic-Maiwald M, Schüpbach R, Weder W, Benden C.
    Pediatr Transplant; 2018 May 15; 22(3):e13145. PubMed ID: 29380491
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 33.